Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Lonapegsomatropin (Skytrofa) Peptide
Long-acting pegylated growth hormone, once-weekly.
What is Lonapegsomatropin (Skytrofa)?
Lonapegsomatropin (Skytrofa) is a gh analog · endocrine peptide studied for pediatric growth hormone deficiency. Below is an educational overview of Lonapegsomatropin (Skytrofa) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Skytrofa
Pediatric growth hormone deficiency (children 1 year and older, ≥11.5 kg).
A once-weekly growth hormone pen that slowly releases natural GH all week — instead of daily shots.
- •Viral infections
- •Cough
- •Fever
- •Hemorrhage
- •Injection-site reactions
- •Increased intracranial pressure
- •Slipped capital femoral epiphysis
- •Progression of scoliosis
- •Glucose intolerance
- •Adrenal/thyroid changes
- •Closed epiphyses
- •Active cancer
- •Acute critical illness
- •Severe respiratory impairment in Prader-Willi syndrome with obesity
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Lonapegsomatropin (Skytrofa) Mechanism of Action
Prodrug of somatropin with a transient PEG linker that releases unmodified GH over ~1 week, providing once-weekly dosing for pediatric GH deficiency.
Lonapegsomatropin (Skytrofa) Research Areas & Benefits
Lonapegsomatropin (Skytrofa) Dosage & Common Research Protocols
0.24 mg/kg SC once weekly.
Protocols summarized for educational reference from published research. Not dosing guidance.
Lonapegsomatropin (Skytrofa) Studies & Cited Research
heiGHt trial
Non-inferior annualized height velocity vs daily somatropin.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Lonapegsomatropin (Skytrofa) Side Effects & Safety Considerations
- •FDA-approved.
- •Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
Common questions about Lonapegsomatropin (Skytrofa)
More Performance peptides · See all 14
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.